The Latest Breaking News from Cardiology

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Incyte shares traded in a range of $71.38 to $72.98 on day volume of 1.25…

Masih Ullah had arrived at the prison 12 days earlier

BALTIMORE -- Doctors learned early in the pandemic that COVID-19 was more than a respiratory disease. It was attacking bodily organs, including the heart — even in healthy, young athletes.

The numbers dying while waiting on an outpatient appointment at the Queen Elizabeth University Hospital have risen.